Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience

Élias, Dominique; Dubé, Pierre; Blot, François; Bonvallot, S.; Eggenspieler, P.; Sabourin, Jean‐Christophe; Ducreux, Michel; Rougier, P; Lasser, P

doi:10.1016/s0748-7983(97)90750-2

Cited by 23 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Assessment Phase: It is imperative to rule out extraperitoneal disease (for example, >3 liver metastases 49,51 or N3 lymph nodes 6,7,15,17,18 ) and to evaluate if a resection is feasible. It is during this phase that the pci is measured (loc a).…”

Section: Surgical Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

et al. 2015

Self Cite

View full text Add to dashboard Cite

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

show abstract

Section: Surgical Considerationsmentioning

confidence: 99%

“…Its origin is often cancers of the gastrointestinal tract, but it can frequently arise from ovarian cancer and breast cancer (mostly the lobular subtype). However, many cancers can metastasize to the peritoneum [1][2][3][4][5][6][7] .…”

mentioning

confidence: 99%

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Results from different international working groups clearly show that cytoreductive surgery alone or combined with hyperthermic chemotherapy is well tolerated and prevents malignant ascites, contrasting with the 6 6 2 2 3 1 6 5 1 1 3 3 4 3 1 0 1 1 0 Pain 0 0 11 12 9 6 6 1 5 1 0 8 7 6 3 2 1 7 8 1 3 2 2 3 9 3 0 0 0 0 4 1 0 0 0 0 0 Ascites 0 0 25 17 15 12 9 1 5 5 3 3 2 1 2 1 [14], which favours an intraperitoneal tumour model in which surgical procedures that include entry into the abdominal cavity result in augmented tumour growth and worse outcome [4,5,[15][16][17]. The mortality is < 6% and the 1-year survival 75%.…”

Section: Discussionmentioning

confidence: 99%

Surgical treatment of disseminated peritoneal metastases from urological cancer: results from a prospective study

Otto

Suhr²,

Krege

et al. 2002

BJU International

View full text Add to dashboard Cite

Objective To report a prospective phase II study of patients with disseminated peritoneal carcinomatosis and symptomatic disease, in whom the peritoneal metastases were resected. Patients and methods From 1995From to 1999 (20 men and 12 women, median age 56 years, range 32-75) with peritoneal carcinomatosis were enrolled in the trial. Pain and ascites were determined according to the National Cancer Institute score/criteria, and performance scored according to the World Health Organisation criteria. Results All patients had intraperitoneal disseminated malignancies with clinically evident ascites, and presented with abdominal pain. The median (range) operative duration was 2.9 (1-5.5) h and the hospital stay 25 (10-44) days, with no deaths at 30 days. The ascites was completely cured in 25 of the 32 patients, pain relieved in 28 and the performance score improved in 25. The median survival time was 1 year; the 1-and 2-year survival rates were 45% and 38%, respectively. Patients with residual metastases after incomplete resection had a significantly worse prognosis, but the prognosis was significantly better in those with a low tumour burden. Conclusions Peritoneal carcinomatosis is treatable; radical peritonectomy improves the performance score in selected patients with cancer-related ascites and/or pain, and is now the standard approach in the authors' Cancer Centre.

show abstract

“…The drug is modified as it enters the cell into an active state [34]. It has been used extensively in intraperitoneal cancer chemotherapy treatment protocols in appendiceal, gastric, and colorectal peritoneal carcinomatosis (PC) patients [8, 24, 35, 36]. Barlogie et al suggested in vitro thermal enhancement of mitomycin C [37].…”

Section: Drugs Used In Perioperative Cancer Chemotherapy Protocolsmentioning

confidence: 99%

Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients

Speeten

Govaerts

Stuart

et al. 2012

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens.Materials and Methods. A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken.Conclusions. There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.

show abstract

Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience

Cited by 23 publications

References 8 publications

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

Surgical treatment of disseminated peritoneal metastases from urological cancer: results from a prospective study

Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients

Contact Info

Product

Resources

About